Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc has demonstrated notable advancements in its clinical drug development and the commercialization of its RenovoCath platform, positioning the company for substantial revenue growth, projected to reach $1.3 million in 2025 and $4.5 million in 2026. The increase in active commercial cancer centers, from five to nine, coupled with well-known institutions like City of Hope and Moffitt Cancer Centers adopting their technology, underscores the expanding market presence and potential demand for its therapies. Furthermore, the company's financial outlook remains attractive, with expectations that RenovoCath sales and ongoing clinical trial progress will act as strong catalysts for future stock performance.

Bears say

The financial outlook for RenovoRx Inc reflects significant challenges, highlighted by a revenue of only $0.3 million against a net loss of $2.9 million, yielding an earnings per share (EPS) of $(0.08), in line with expectations but insufficient to suggest near-term financial viability. The company's focus on developing therapies for pancreatic cancer, which has a notably poor 5-year survival rate of just 12%, amplifies concerns regarding the effectiveness and market demand for its product candidates amid a backdrop of fierce competition and regulatory hurdles. Furthermore, persistent risks related to liquidity, product efficacy, and broader market sentiments surrounding biotech investments further contribute to a negative perception of the company's financial sustainability.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.